Terminated and withdrawn trials of ADCs
| Agent | Trial identifier | Status | Reason for termination/withdrawal |
|---|---|---|---|
| Rovalpituzumab tesirine | NCT02709889 | Terminated | Strategic considerations |
| Rovalpituzumab tesirine | NCT02819999 | Terminated | Strategic considerations |
| Rovalpituzumab tesirine | NCT03026166 | Terminated | Enrollment was stopped after the dose-limiting toxicity (DLT) evaluation phase of cohort 2 |
| Rovalpituzumab tesirine | NCT03033511 | Terminated | Independent Data Monitoring Committee recommendation |
| Rovalpituzumab tesirine | NCT03334487 | Withdrawn | Strategic considerations |
| HS-20093 | NCT06052423 | Withdrawn | Research and development strategy adjustment |
| Tusamitamab ravtansine | NCT02187848 | Terminated | Sponsor decision |
ADCs: antibody drug conjugates